Get startedLog in
    Picture of Genmab A/S logo

    GMAB — Genmab A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapFalling Star
    All News

    Brief: Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical Significance

    Picture of Genmab A/S logoGenmab A/S
    16/01/2026 18:37
    Jan 16 (Reuters) - Genmab A/S GMAB.CO:

GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

GENMAB: STUDY OS DID NOT REACH STATISTICAL SIGNIFICANCE

GENMAB: STUDY DEMONSTRATED AN OVERALL SURVIVAL OF HR: 0.96

GENMAB - CO AND ABBVIE WILL ENGAGE WITH GLOBAL REGULATORY AUTHORITIES TO DISCUSS NEXT STEPS

GENMAB: DATA IS ANTICIPATED IN 2026 FROM TWO PHASE 3 TRIALS

Source text: ID:nGNX9tbFD

Further company coverage: GMAB.CO

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Genmab A/S

    See all news